Stephanie Davis
Stock Analyst at Barclays
(0.79)
# 3,903
Out of 4,944 analysts
95
Total ratings
33.82%
Success rate
-116.46%
Average return
Main Sectors:
Stocks Rated by Stephanie Davis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DGX Quest Diagnostics | Maintains: Equal-Weight | $175 → $185 | $179.04 | +3.33% | 5 | Apr 23, 2025 | |
| WAY Waystar Holding | Maintains: Overweight | $50 → $45 | $35.35 | +27.30% | 6 | Apr 14, 2025 | |
| OPRX OptimizeRx | Maintains: Equal-Weight | $11 → $5 | $17.33 | -71.15% | 3 | Nov 14, 2024 | |
| DOCS Doximity | Maintains: Overweight | $52 → $75 | $64.02 | +17.15% | 5 | Nov 11, 2024 | |
| LFST LifeStance Health Group | Maintains: Underweight | $6 → $7 | $5.17 | +35.40% | 2 | Nov 11, 2024 | |
| GDRX GoodRx Holdings | Maintains: Overweight | $10 → $6 | $3.56 | +68.54% | 7 | Nov 11, 2024 | |
| EVH Evolent Health | Maintains: Overweight | $39 → $19 | $8.97 | +111.82% | 1 | Nov 11, 2024 | |
| COR Cencora | Maintains: Overweight | $263 → $290 | $291.04 | -0.36% | 2 | Nov 7, 2024 | |
| PINC Premier | Maintains: Equal-Weight | $20 → $24 | $24.53 | -2.14% | 3 | Nov 6, 2024 | |
| CAH Cardinal Health | Maintains: Overweight | $117 → $133 | $148.12 | -10.21% | 2 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $39 → $58 | $31.35 | +85.01% | 2 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2 → $3 | $2.58 | +16.28% | 7 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $213 → $249 | $272.54 | -8.64% | 3 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $29 | $28.65 | +1.22% | 11 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $34 | $7.44 | +356.99% | 9 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $59 → $34 | $23.06 | +47.44% | 3 | Jan 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $242 → $233 | $279.18 | -16.54% | 9 | Dec 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $17 | $3.22 | +427.95% | 10 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $76 | $89.27 | -14.87% | 5 | Jun 7, 2022 |
Quest Diagnostics
Apr 23, 2025
Maintains: Equal-Weight
Price Target: $175 → $185
Current: $179.04
Upside: +3.33%
Waystar Holding
Apr 14, 2025
Maintains: Overweight
Price Target: $50 → $45
Current: $35.35
Upside: +27.30%
OptimizeRx
Nov 14, 2024
Maintains: Equal-Weight
Price Target: $11 → $5
Current: $17.33
Upside: -71.15%
Doximity
Nov 11, 2024
Maintains: Overweight
Price Target: $52 → $75
Current: $64.02
Upside: +17.15%
LifeStance Health Group
Nov 11, 2024
Maintains: Underweight
Price Target: $6 → $7
Current: $5.17
Upside: +35.40%
GoodRx Holdings
Nov 11, 2024
Maintains: Overweight
Price Target: $10 → $6
Current: $3.56
Upside: +68.54%
Evolent Health
Nov 11, 2024
Maintains: Overweight
Price Target: $39 → $19
Current: $8.97
Upside: +111.82%
Cencora
Nov 7, 2024
Maintains: Overweight
Price Target: $263 → $290
Current: $291.04
Upside: -0.36%
Premier
Nov 6, 2024
Maintains: Equal-Weight
Price Target: $20 → $24
Current: $24.53
Upside: -2.14%
Cardinal Health
Nov 4, 2024
Maintains: Overweight
Price Target: $117 → $133
Current: $148.12
Upside: -10.21%
Oct 31, 2024
Maintains: Equal-Weight
Price Target: $39 → $58
Current: $31.35
Upside: +85.01%
Oct 29, 2024
Maintains: Equal-Weight
Price Target: $2 → $3
Current: $2.58
Upside: +16.28%
Aug 2, 2024
Maintains: Equal-Weight
Price Target: $213 → $249
Current: $272.54
Upside: -8.64%
Jan 3, 2024
Initiates: Overweight
Price Target: $29
Current: $28.65
Upside: +1.22%
Feb 23, 2023
Upgrades: Outperform
Price Target: $34
Current: $7.44
Upside: +356.99%
Jan 5, 2023
Downgrades: Market Perform
Price Target: $59 → $34
Current: $23.06
Upside: +47.44%
Dec 2, 2022
Maintains: Outperform
Price Target: $242 → $233
Current: $279.18
Upside: -16.54%
Nov 9, 2022
Maintains: Outperform
Price Target: $20 → $17
Current: $3.22
Upside: +427.95%
Jun 7, 2022
Maintains: Outperform
Price Target: $67 → $76
Current: $89.27
Upside: -14.87%